Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

101. Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness

Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness | CADTH.ca Find the information you need Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness Published on: December 12, 2016 Project Number: RC0829-000 Product Line: Research (...) Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the cost-effectiveness of denosumab versus zoledronic acid in patients with osteoporosis? Key Message Two studies were identified that evaluated the cost-effectiveness of denosumab for the treatment of elderly men with osteoporosis, from a payer perspective in the United States or Sweden. Both studies found that subcutaneous denosumab 60 mg administered once every six months was associated with lower-costs

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

102. Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines

Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines Published on: November 28, 2016 Project Number: RC0828-000 Product (...) Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of denosumab versus zoledronic acid in male patients with osteoporosis? What is the comparative clinical effectiveness of denosumab versus zoledronic acid in male patients with osteoporosis and non-metastatic prostate cancer receiving adjuvant anti-androgen therapy? What are the evidence-based guidelines regarding the use of denosumab and zoledronic acid

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

103. Lifestyle-Related Metabolic Disorders, Osteoporosis, and Fracture Risk in Asia: A Systematic Review. (PubMed)

Lifestyle-Related Metabolic Disorders, Osteoporosis, and Fracture Risk in Asia: A Systematic Review. The prevalence of both lifestyle-related metabolic disorders and osteoporosis is increasing in Asia.To conduct a systematic review of the published literature to identify studies examining disorders of glucose and lipid metabolism (type 2 diabetes, hyperglycemia, hypercholesterolemia, hyperlipidemia, dyslipidemia, metabolic syndrome [MetS], and atherosclerosis) as risk factors for osteoporosis (...) than did subjects without diabetes (risk estimate range 1.26-4.73). Two studies found that subjects with atherosclerosis had a significantly higher risk of fracture (risk estimate range 1.10-2.52). Studies consistently reported that MetS is likely associated with osteoporosis or decreased BMD in men but not women. No consistent association was found for diabetes and BMD, with studies reporting contrasting results. There was limited evidence investigating lipid metabolism and hyperglycemia and risk

Full Text available with Trip Pro

2016 Value in health regional issues

104. The Occurrence of Subclinical Hypercortisolism and Osteoporosis in Patients with Incidentally Discovered Unilateral and Bilateral Adrenal Tumors (PubMed)

The Occurrence of Subclinical Hypercortisolism and Osteoporosis in Patients with Incidentally Discovered Unilateral and Bilateral Adrenal Tumors Adrenal incidentalomas (AI) are clinically silent adrenal masses that are detected incidentally during imaging procedures performed for unrelated diseases. The aim of this study was to investigate the prevalence of sub-clinical hypercortisolism (SH) and associated co-morbidities in patients with unilateral AI (UAI) and bilateral AI (BAI).We evaluated (...) , and diabetes, hypertension and dyslipidemia occurred with similar frequency in both groups. The overall prevalence of SH was 20.5% based on post-1 mg DST, and 20.0% based on post-LDDST cortisol levels, and it was more prevalent in BAI than UAI patients (31.1% vs 15.2%, respectively, p=0.026). LS BMD was lower in BAI than in UAI patients (0.96±0.14 vs 0.87±0.15, p=0.002). There were no differences in FN BMD. The prevalence of osteoporosis was higher in BAI compared to UAI patients (37.1% vs 15.9

Full Text available with Trip Pro

2016 Journal of medical biochemistry

105. Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. (PubMed)

Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Calcium is the dominant mineral present in bone and a shortfall nutrient in the American diet. Supplements have been recommended for persons who do not consume adequate calcium from their diet as a standard strategy for the prevention of osteoporosis (...) and related fractures. Whether calcium with or without vitamin D supplementation is beneficial or detrimental to vascular health is not known.The National Osteoporosis Foundation and American Society for Preventive Cardiology convened an expert panel to evaluate the effects of dietary and supplemental calcium on cardiovascular disease based on the existing peer-reviewed scientific literature. The panel considered the findings of the accompanying updated evidence report provided by an independent evidence

Full Text available with Trip Pro

2016 Annals of Internal Medicine

106. Love your bones: finding and treating osteoporosis

Love your bones: finding and treating osteoporosis Love your bones: finding and treating osteoporosis - Evidently Cochrane Search and hit Go By October 20, 2016 // Today is World Osteoporosis Day. We’re taking a look at the campaign and at Cochrane evidence on osteoporosis. Be proactive and #LoveYourBones is the message of this year’s . The campaign is a call to action for members of the public to act early to protect their bone and muscle health, and for health professionals and those who fund (...) health care to prioritize osteoporosis and fracture prevention by ensuring that people who are at high risk are assessed and offered appropriate treatment. People are also being asked to raise awareness of the campaign by wearing white, not a colour that does anything for me, so instead I’m blogging some Cochrane evidence. What is osteoporosis? Osteoporosis is a condition that weakens bones through a reduction in bone mineral density (BMD), making the risk of broken bones (fractures) more likely

2016 Evidently Cochrane

107. Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses. (PubMed)

Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses. Osteoporosis is an under-recognized problem threatening men. Bisphosphonates are the main treatment but their comparative efficacy is unclear for men with osteoporosis. Therefore, we performed this systematic review with network meta-analyses to summarize the evidence of comparative efficacy of bisphosphonates in men with osteoporosis.We completed network meta (...) -analyses with a frequentist model to compare the efficacy of different bisphosphonates. Randomized controlled trials investigating bisphosphonates used in men with osteoporosis were included. The primary outcome was the rate of patients with a new vertebral fracture. The secondary outcome was the rate of patients with a non-vertebral fracture, which was defined as any fractures reported other than vertebral fractures. Pairwise meta-analyses were performed to compare bisphosphonates with placebo. We

Full Text available with Trip Pro

2016 Rheumatology and therapy

108. Prevalence of Osteoporosis and Its Risk Factors in Men with COPD in Qazvin (PubMed)

Prevalence of Osteoporosis and Its Risk Factors in Men with COPD in Qazvin Introduction. Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Proper diagnosis of osteoporosis as a systemic adverse effect of COPD is of significant importance. The present study aimed at evaluating the prevalence of osteoporosis and its risk factors in men suffering from COPD in Qazvin (2014). Methods. This descriptive-analytical study was conducted on 90 patients (...) with COPD using random sampling. Anthropometric data and results from physical examination were collected. Pulmonary function test and bone mineral densitometry were done for all participants as well. Results. The prevalence of osteopenia and osteoporosis in COPD patients was 31.5 and 52.8 percent, respectively. Bone mineral density (BMD) at the femoral neck was associated significantly with body mass index (BMI), increased severity of COPD, and use of oral corticosteroid (P < 0.05). Conclusion

Full Text available with Trip Pro

2016 International journal of chronic diseases

109. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. (PubMed)

Romosozumab Treatment in Postmenopausal Women with Osteoporosis. Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption.We enrolled 7180 postmenopausal women who had a T score of -2.5 to -3.5 at the total hip or femoral neck. Patients were randomly assigned to receive subcutaneous injections of romosozumab (at a dose of 210 mg) or placebo monthly for 12 months; thereafter, patients in each group received denosumab for 12 months (...) the transition to denosumab (0.6% [21 of 3325 patients] in the romosozumab group vs. 2.5% [84 of 3327] in the placebo group, a 75% lower risk with romosozumab; P<0.001). Adverse events, including instances of hyperostosis, cardiovascular events, osteoarthritis, and cancer, appeared to be balanced between the groups. One atypical femoral fracture and two cases of osteonecrosis of the jaw were observed in the romosozumab group.In postmenopausal women with osteoporosis, romosozumab was associated with a lower

Full Text available with Trip Pro

2016 NEJM

110. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. (PubMed)

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor.To determine the efficacy and safety of abaloparatide, 80 μg, vs placebo for prevention of new vertebral fracture in postmenopausal women at risk of osteoporotic fracture.The Abaloparatide Comparator Trial (...) greater with abaloparatide than placebo (all P < .001). Incidence of hypercalcemia was lower with abaloparatide (3.4%) vs teriparatide (6.4%) (risk difference [RD], −2.96 [95%CI, −5.12 to −0.87]; P = .006). [table: see text].Among postmenopausal women with osteoporosis, the use of subcutaneous abaloparatide, compared with placebo, reduced the risk of new vertebral and nonvertebral fractures over 18 months. Further research is needed to understand the clinical importance of RD, the risks and benefits

Full Text available with Trip Pro

2016 JAMA

111. [Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"]

[Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"] Systematische leitlinienrecherche und -bewertung sowie extraktion relevanter empfehlungen für ein DMP osteoporose: abschlussbericht; auftrag V14-0 [Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"] Systematische leitlinienrecherche und -bewertung sowie extraktion relevanter empfehlungen für ein DMP (...) osteoporose: abschlussbericht; auftrag V14-0 [Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen

2016 Health Technology Assessment (HTA) Database.

112. Diagnosis and Management of Osteoporosis

Diagnosis and Management of Osteoporosis DIAGNOSIS AND MANAGEMENT OF OSTEOPOROSIS Clinical Practice Guideline | February 2016 These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making. OBJECTIVE Alberta clinicians will understand who and how to screen, assess, diagnose, treat and manage osteoporosis (...) and/or fracture risk. TARGET POPULATION All men and women 50 years of age and older EXCLUSIONS All men and women under 50 years of age This guideline is partially adapted from Papaioannou A, Morin S, Cheung AM, et al; for the Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. CMAJ. 2010;182:1864-73. 1 KEY MESSAGES ? The goal is to find patients at high risk of fracture, not just low bone mineral density

2016 Toward Optimized Practice

113. Alendronic Acid / Colecalciferol Mylan - postmenopausal osteoporosis in women at risk of vitamin D deficiency

Alendronic Acid / Colecalciferol Mylan - postmenopausal osteoporosis in women at risk of vitamin D deficiency 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 24 June 2016 EMA/354096/2016 EMEA/H/C/004172 Questions and answers (...) Withdrawal of the marketing authorisation application for Alendronic Acid/Colecalciferol Mylan (alendronic acid and colecalciferol) On 27 May 2016, Mylan SAS officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Alendronic Acid/Colecalciferol Mylan, for the treatment of postmenopausal osteoporosis in women at risk of vitamin D deficiency. What is Alendronic Acid/Colecalciferol Mylan? Alendronic Acid

2016 European Medicines Agency - EPARs

114. Postmenopausal Osteoporosis. (PubMed)

Postmenopausal Osteoporosis. 27223157 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2096-7 10.1056/NEJMc1602599 Black Dennis M DM Rosen Clifford J CJ eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2095 27223158 N Engl J Med. 2016 May 26;374(21):2095-6 (...) 27223159 N Engl J Med. 2016 May 26;374(21):2096 27223160 Bone Density Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223157 10.1056/NEJMc1602599 10.1056/NEJMc1602599#SA4

Full Text available with Trip Pro

2016 NEJM

115. Postmenopausal Osteoporosis. (PubMed)

Postmenopausal Osteoporosis. 27223158 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2095 10.1056/NEJMc1602599 Michaëlsson Karl K Uppsala University, Uppsala, Sweden karl.michaelsson@surgsci.uu.se. Aspenberg Per P Linköping University, Linköping, Sweden. eng 88225-1 CIHR Canada Letter Comment United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med (...) . 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2096-7 27223157 Bone Density Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223158 10.1056/NEJMc1602599 PMC5104560 CAMS6243 10.1056/NEJMc1602599#SA1 N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 BMJ. 2015 May 26;350:h2088 26013536 Osteoporos Int. 2016 Jan;27(1):417

Full Text available with Trip Pro

2016 NEJM

116. Postmenopausal Osteoporosis. (PubMed)

Postmenopausal Osteoporosis. 27223159 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2095-6 10.1056/NEJMc1602599 Ott Susan M SM University of Washington, Seattle, WA smott@uw.edu. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2096-7 27223157 Bone Density (...) Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223159 10.1056/NEJMc1602599 10.1056/NEJMc1602599#SA2

Full Text available with Trip Pro

2016 NEJM

117. Postmenopausal Osteoporosis. (PubMed)

Postmenopausal Osteoporosis. 27223160 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2096 10.1056/NEJMc1602599 Cheung Angela M AM University of Toronto, Toronto, ON, Canada angela.cheung@uhn.ca. Papaioannou Alexandra A McMaster's University, Hamilton, ON, Canada. Morin Suzanne S McGill University, Montreal, QC, Canada. Osteoporosis Canada Scientific Advisory Council eng Letter Comment United States N Engl J Med (...) 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2096-7 27223157 Bone Density Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223160 10.1056/NEJMc1602599 10.1056/NEJMc1602599#SA3

Full Text available with Trip Pro

2016 NEJM

118. Relationships between serum Omentin-1 levels and bone mineral density in older men with osteoporosis (PubMed)

Relationships between serum Omentin-1 levels and bone mineral density in older men with osteoporosis To investigate the correlation between serum Omentin-1 levels and the presence of osteoporosis in older men.Serum Omentin-1, bone turnover biochemical markers, and bone mineral density (BMD) were determined in 45 older men with osteoporosis or 45 older men without osteoporosis (65-70 years old).Omentin-1 levels were increased in older men with osteoporosis, and the differences remained (...) with osteoporosis and control groups that were considered separately.Omentin-1 is an independent predictor of BMD in older men with osteoporosis, and it is negatively correlated with bone turnover biochemical markers. It is suggested that Omentin-1 may exert a negative effect on bone mass through the regulation of the osteoblast differentiation in the older men with osteoporosis.

Full Text available with Trip Pro

2016 Chronic diseases and translational medicine

119. Treatment for osteoporosis in people with ß-thalassaemia. (PubMed)

Treatment for osteoporosis in people with ß-thalassaemia. Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fracture. Osteoporosis represents an important cause of morbidity in people with beta-thalassaemia and its pathogenesis is multifactorial. Factors include bone marrow expansion due to ineffective erythropoiesis, resulting in reduced trabecular (...) bone tissue with cortical thinning; endocrine dysfunction secondary to excessive iron loading, leading to increased bone turnover; and lastly, a predisposition to physical inactivity due to disease complications with a subsequent reduction in optimal bone mineralization.A number of therapeutic strategies have been applied to treat osteoporosis in people with beta-thalassaemia, which include bisphosphonates, with or without, hormone replacement therapy. There are various forms of bisphosphonates

Full Text available with Trip Pro

2016 Cochrane

120. Comparison of unilateral versus bilateral percutaneous kyphoplasty for the treatment of patients with osteoporosis vertebral compression fracture (OVCF): a systematic review and meta-analysis. (PubMed)

Comparison of unilateral versus bilateral percutaneous kyphoplasty for the treatment of patients with osteoporosis vertebral compression fracture (OVCF): a systematic review and meta-analysis. To compare the short- and long-term clinical outcomes, operation times, restoration rate, dosage of polymethylmeth-acrylate (PMMA) injected, complications and X-rays exposure frequency between unilateral and bilateral kyphoplasty approaches for the treatment of OVCF.Systematic review and meta

2016 European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society